Question 1

What is PALIVIZUMAB used for?

Accepted Answer

PALIVIZUMAB (brand name Synagis) is a Biologic / Monoclonal Antibody indicated for with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season.

Question 2

How does PALIVIZUMAB work?

Accepted Answer

PALIVIZUMAB works through the following mechanism: 12.1 Mechanism of Action Palivizumab is a recombinant humanized monoclonal antibody with anti-RSV activity [see Microbiology ( 12.4 ) ]..

Question 3

What are the most common side effects of PALIVIZUMAB?

Accepted Answer

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for PALIVIZUMAB. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Question 4

Is PALIVIZUMAB the same as Synagis?

Accepted Answer

Synagis is a brand name for PALIVIZUMAB. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

PALIVIZUMAB

Mechanism of Action

Indications

FDA Warnings

Known Side Effects

Community Discussions

Primary sources

Compare With

Formulations